The investigators published the final analysis of the MOMENTUM 3 trial comparing the fully magnetically levitated centrifugal continuous-flow HeartMate 3 pump to the mechanical-bearing axial continuous-flow HeartMate II pump. The composite primary end point was survival at two years free of disabling stroke or reoperation to replace or remove a malfunctioning device. The principal secondary end point was pump replacement at two years.
HeartMate 3 and HeartMate II were implanted in 516 and 512 patients, respectively. In the analysis of the primary end point, 397 patients (76.9%) with HeartMate 3, as compared with 332 (64.8%) with HeartMate II, remained alive and free of disabling stroke or reoperation to replace or remove a malfunctioning device at two years (relative risk, 0.84; 95% confidence interval [CI], 0.78 to 0.91; P
You are here:
A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report
Source: The New England Journal of Medicine
Keywords:
Author(s): Mandeep R. Mehra, Nir Uriel, Yoshifumi Naka, Joseph C. Cleveland, Jr., Melana Yuzefpolskaya, Christopher T. Salerno, Mary N. Walsh, Carmelo A. Milano, Chetan B. Patel, Steven W. Hutchins, John Ransom, Gregory A. Ewald, Akinobu Itoh, Nirav Y. Raval, Scott C. Silvestry, Rebecca Cogswell, Ranjit John, Arvind Bhimaraj, Brian A. Bruckner, Brian D. Lowes, John Y. Um, Valluvan Jeevanandam, Gabriel Sayer, Abeel A. Mangi, Ezequiel J. Molina, Farooq Sheikh, Keith Aaronson, Francis D. Pagani, William G. Cotts, Antone J. Tatooles, Ashok Babu, Don Chomsky, Jason N. Katz, Paul B. Tessmann, David Dean, Arun Krishnamoorthy, Joyce Chuang, Ia Topuria, Poornima Sood, Daniel J. Goldstein, for the MOMENTUM 3 Investigators
1 Comment
There was no significant difference in overall survival between the groups